Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Compass Therapeutics, Inc. (CMPX : NSDQ)

• Company Description    Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. The company's lead product candidate includes CTX-471. Compass Therapeutics Inc. is based in Boston, MA. Number of Employees: 24

• Price / Volume Information    Yesterday's Closing Price: $2.67 Daily Weekly Monthly 20 Day Moving Average: 272,359 shares Shares Outstanding: 101.28 (millions) Market Capitalization: $270.43 (millions) Beta: 52 Week High: $5.92 52 Week Low: $1.25 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 76.82% 93.75% 12 Week 11.25% 20.71% Year To Date -15.77% 0.16%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 80 GUEST STREET SUITE 601 - BOSTON,MA 02135 USA ph: 617-500-8099 fax: - ir@compasstherapeutics.com http://www.compasstherapeutics.com

• General Corporate Information    Officers Thomas J. Schuetz - Chief Executive Officer Vered Bisker-Leib - President and Chief Operating Officer Carl L. Gordon - Chairman Phil Ferneau - Director Steven Squinto - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 20454B104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 101.28 Most Recent Split Date: (:1) Beta: Market Capitalization: $270.43 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.35 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.01 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 53.33% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -100.11 12/31/21 - -145.25 09/30/21 - -245.97 ROA 03/31/22 - -87.13 12/31/21 - -118.36 09/30/21 - -176.47 Current Ratio 03/31/22 - 15.03 12/31/21 - 13.84 09/30/21 - 3.72 Quick Ratio 03/31/22 - 15.03 12/31/21 - 13.84 09/30/21 - 3.72 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 1.33 12/31/21 - 1.43 09/30/21 - 0.39 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©